Lamicone Z Tablet contains Lamivudine 150mg and Zidovudine 300mg, a highly effective antiretroviral therapy (ART) formulation indicated for the management of HIV infection. It helps in reducing viral replication, controlling viral load, and supporting the immune system in HIV-positive patients.
This combination works synergistically: Lamivudine and Zidovudine inhibit reverse transcriptase at different stages, providing robust suppression of HIV replication. Regular use under medical supervision helps maintain immune function and improves patient outcomes.
For distributors and healthcare suppliers, Lamicone Z Tablet is a high-demand ART product, widely prescribed in HIV clinics, hospitals, and infectious disease centers. The increasing prevalence of HIV and the need for reliable combination therapy ensure continuous market demand.
Adding Lamicone Z Tablet to your antiretroviral and viral suppression segment provides strong opportunities in pharmacies, hospital supply chains, HIV care centers, export markets, and third-party manufacturing. Its proven clinical efficacy, patient adherence, and broad therapeutic application make it a valuable addition for pharmaceutical distribution.